Agios has leveraged its core capabilities in cellular metabolism to build a product engine that is focused in the therapeutic areas of cancer and rare genetic disorders of metabolism.
|DISEASE||PROGRAM||STUDY PHASE||STATUS||LEARN MORE|
|Acute Myeloid Leukemia||ENASIDENIB||Phase 3 IDHENTIFY Study – An Efficacy and Safety Study of enasidenib (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation||Recruiting||clinicaltrials.gov|
|Acute Myeloid Leukemia||ENASIDENIB||Phase 1/2 Study of Enasidenib in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation||Active, not recruiting||clinicaltrials.gov|
|Acute Myeloid Leukemia||ENASIDENIB or IVOSIDENIB||Phase 1b Safety Study of Ivosidenib or Enasidenib in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation||Recruiting||clinicaltrials.gov|
|Acute Myeloid Leukemia||ENASIDENIB or IVOSIDENIB||Phase 1/2 Safety and Efficacy Study of Oral Ivosidenib Plus Subcutaneous Azacitidine and Oral Enasidenib Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)||Recruiting||clinicaltrials.gov|
|Acute Myeloid Leukemia||IVOSIDENIB||Phase 1 Study of Orally Administered Ivosidenib in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation||Recruiting||clinicaltrials.gov|
|Solid Tumors (including Glioma)||IVOSIDENIB||Phase 1 Study of Orally Administered Ivosidenib in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation||Active, not recruiting||clinicaltrials.gov|
|Cholangiocarcinoma||IVOSIDENIB||Phase 3 Study of Orally Administered Ivosidenib in Previously Treated Advanced Cholangiocarcinoma Patients With IDH1 Mutations||Recruiting||clinicaltrials.gov
|Solid Tumors (including Glioma)||AG-881||Phase 1 Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation||Recruiting||clinicaltrials.gov|
|Solid Tumors||ENASIDENIB||Study of Orally Administered Enasidenib in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation||Completed||clinicaltrials.gov|
|Pyruvate kinase deficiency||AG-348||Phase 2 DRIVE PK Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency||Active, not recruiting||clinicaltrials.gov
|Pyruvate kinase deficiency||AG-348||A Phase 1 SAD Study of AG-348 in Healthy Volunteers||Completed||clinicaltrials.gov|
|Pyruvate kinase deficiency||AG-348||A Phase 1 MAD Study of AG-348 in Healthy Volunteers||Completed||clinicaltrials.gov|
|Pyruvate kinase deficiency||Non-interventional||Natural History Study of Pyruvate Kinase Deficiency – led by Boston Children's||Active, not recruiting||clinicaltrials.gov|
The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.